[HTML][HTML] Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease
C Zhu, Q Huai, X Zhang, H Dai, X Li… - International Journal of …, 2023 - ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease (NAFLD), as one of the main causes of chronic liver disease
worldwide, encompasses a spectrum of liver conditions that are not caused by other …
worldwide, encompasses a spectrum of liver conditions that are not caused by other …
Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD
D Ezhilarasan - Metabolism, 2024 - Elsevier
Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-α/γ agonist,
has been used to treat metabolic diseases such as insulin resistance and diabetic …
has been used to treat metabolic diseases such as insulin resistance and diabetic …
S1PR1/S1PR3-YAP signaling and S1P-ALOX15 signaling contribute to an aggressive behavior in obesity-lymphoma
X Wang, W Guo, X Shi, Y Chen, Y Yu, B Du… - Journal of Experimental …, 2023 - Springer
Background Excess body weight has been found to associate with an increased risk of
lymphomas and some metabolic pathways are currently recognized in lymphomagenesis …
lymphomas and some metabolic pathways are currently recognized in lymphomagenesis …
Characterization of lipid signatures in the plasma and insulin-sensitive tissues of the C57BL/6J mice fed on obesogenic diets
Diet-induced obesity mouse models are widely utilized to investigate the underlying
mechanisms of dyslipidemia, glucose intolerance, insulin resistance, hepatic steatosis, and …
mechanisms of dyslipidemia, glucose intolerance, insulin resistance, hepatic steatosis, and …
Harnessing the Therapeutic Potential of Ginsenoside Rd for Activating SIRT6 in Treating a Mouse Model of Nonalcoholic Fatty Liver Disease
T Cui, X Xiao, Z Pan, K Tang, Y Zhong, Y Chen… - ACS …, 2023 - ACS Publications
Nonalcoholic fatty liver disease (NAFLD) is a prevalent global condition and a common
precursor to liver cancer, yet there is currently no specific medication available for its …
precursor to liver cancer, yet there is currently no specific medication available for its …
PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis
ZY Zhang, Q Yan, WH Wu, Y Zhao… - Journal of …, 2023 - journals.sagepub.com
Objective To undertake a network meta-analysis to compare the relative efficacy of a dual
peroxisome proliferator-activated receptor (PPAR) α and PPARγ agonist, glucagon-like …
peroxisome proliferator-activated receptor (PPAR) α and PPARγ agonist, glucagon-like …
[HTML][HTML] Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice
We evaluated the effects of select herbal extracts (Tinospora cordifolia [TC], Tinospora
cordifolia with Piper longum [TC+ PL], Withania somnifera [WS], Glycyrrhiza glabra [GG] …
cordifolia with Piper longum [TC+ PL], Withania somnifera [WS], Glycyrrhiza glabra [GG] …
A methionine-choline-deficient diet induces nonalcoholic steatohepatitis and alters the lipidome, metabolome, and gut microbiome profile in the C57BL/6J mouse
J Gautam, H Aggarwal, D Kumari, SK Gupta… - … et Biophysica Acta (BBA …, 2024 - Elsevier
The methionine-choline-deficient (MCD) diet-induced non-alcoholic steatohepatitis (NASH)
in mice is a well-established model. Our study aims to elucidate the factors influencing liver …
in mice is a well-established model. Our study aims to elucidate the factors influencing liver …
Comparative profiling of gut microbiota and metabolome in diet-induced obese and insulin-resistant C57BL/6J mice
Diet-based models are commonly used to investigate obesity and related disorders. We
conducted a comparative profiling of three obesogenic diets HFD, high fat diet; HFHF, high …
conducted a comparative profiling of three obesogenic diets HFD, high fat diet; HFHF, high …
[HTML][HTML] Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver …
M Zhou, X Liu, Y Wu, Q Xiang, R Yu - Journal of Ethnopharmacology, 2024 - Elsevier
Ethnopharmacological relevance Hepatic steatosis, a hallmark of non-alcoholic fatty liver
disease (NAFLD), represents a significant global health issue. Liver lipidomics has garnered …
disease (NAFLD), represents a significant global health issue. Liver lipidomics has garnered …